Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ERr 731 is a standardized extract of the root of *Rheum rhaponticum* (Siberian rhubarb), developed as a nonhormonal therapy primarily for the relief of menopausal symptoms—particularly hot flashes, night sweats, anxiety, mood disturbances, and related symptoms. ERr 731 has been used in Europe since the 1990s and has an established safety profile supported by clinical trials and postmarketing surveillance. Its principal mechanism of action is selective agonism of the estrogen receptor beta (ERβ), without significant activation of estrogen receptor alpha (ERα), resulting in relief of menopausal symptoms without the risks typically associated with conventional hormone therapies. The extract is contraindicated in individuals with known or suspected estrogen-dependent cancers. ERr 731 is distributed under various trade names in Europe and North America and is available as a nonprescription product in multiple countries[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ERr 731.